Bayesian guidance released
This article was originally published in The Gray Sheet
FDA says its Feb. 5 guidance on applying Bayesian statistics in medical device trials will help streamline device pivotal studies. The document finalizes a 2006 draft version and includes updates based on several years of input from industry and others. CDRH has been accepting pre-market submissions including Bayesian statistics since the late 1990s, but it has ramped up staff with expertise in the techniques since releasing the 2006 draft (1"The Gray Sheet" July 31, 2006). By allowing sponsors to incorporate data from prior studies, Bayesian statistics makes it possible to yield sufficient trial results from smaller or shorter trials (2"The Gray Sheet" May 31, 2004)
You may also be interested in...
FDA's device center continues to ramp up its resources to deal with a potential influx of PMA submissions that rely on an advanced statistical technique that can speed up clinical trials
FDA is encouraging medical device firms to consider using Bayesian estimation in clinical trials to streamline regulatory timeframes
Keeping Track: Submissions Galore Start The New Year; US FDA Clears New Indications For Enhertu, Xalkori
The latest drug development news and highlights from the Pink Sheet US FDA Performance Tracker